RA0065

antibody from Oursmab

Targeting: CCR4 CC-CKR-4, CD194, ChemR13, CKR4, CMKBR4, k5-5

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0065

Provider

Oursmab

Product name

Mogamulizumab (Biosimilar Reference Antibody) (CCR4)

Antibody type

Monoclonal

Description

Mogamulizumab is a humanized, glycoengineered IgG1¦Ê monoclonal antibody that targets CC chemokine receptor 4 (CCR4), a G protein-coupled receptor expressed on regulatory T cells (Tregs) and Th2 cells. Its Fc region is engineered to enhance antibody-dependent cellular cytotoxicity (ADCC). By binding to CCR4, mogamulizumab selectively depletes CCR4-expressing T-cell subsets, particularly Tregs that suppress anti-tumor immunity. It is approved for the treatment of mycosis fungoides (MF) and S¨¦zary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL), in adult patients who have received at least one prior systemic therapy. It is administered via intravenous infusion.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.